Journal article
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection
SE Olsson, SK Kjaer, K Sigurdsson, OE Iversen, M Hernandez-Avila, CM Wheeler, G Perez, DR Brown, LA Koutsky, EH Tay, P García, KA Ault, SM Garland, S Leodolter, GWK Tang, DG Ferris, J Paavonen, M Lehtinen, M Steben, FX Bosch Show all
Human Vaccines | LANDES BIOSCIENCE | Published : 2009
DOI: 10.4161/hv.5.10.9515
Abstract
Objective: In the quadrivalent (types 6/11/16/18) HPV vaccine (GARDASIL®/SILGARD®) clinical program, 73% of women aged 16-26 were naïve to all vaccine HPV types. In these women, prophylactic administration of the vaccine was highly effective in preventing HPV 6/11/16/18-related cervical disease. Of the remaining women, 15% of had evidence of past infection with one or more vaccine HPV types (seropositive and DNA negative) at the time of enrollment. Here we present an analysis in this group of women to determine the efficacy of the HPV 6/11/16/18 vaccine against new cervical and external anogenital disease related to the same vaccine HPV type which had previously been cleared. Vaccine tolerab..
View full abstractGrants
Funding Acknowledgements
Source of Funding: Merck Research Laboratories, a Division of Merck & Company, Inc., funded these studies.